These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Partial Adenosine A1 Agonist in Heart Failure. Dinh W; Albrecht-Küpper B; Gheorghiade M; Voors AA; van der Laan M; Sabbah HN Handb Exp Pharmacol; 2017; 243():177-203. PubMed ID: 27770217 [TBL] [Abstract][Full Text] [Related]
3. Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A Meibom D; Albrecht-Küpper B; Diedrichs N; Hübsch W; Kast R; Krämer T; Krenz U; Lerchen HG; Mittendorf J; Nell PG; Süssmeier F; Vakalopoulos A; Zimmermann K ChemMedChem; 2017 May; 12(10):728-737. PubMed ID: 28488817 [TBL] [Abstract][Full Text] [Related]
4. Stimulation of the adenosine A3 receptor, not the A1 or A2 receptors, promote neurite outgrowth of retinal ganglion cells. Nakashima KI; Iwao K; Inoue T; Haga A; Tsutsumi T; Mochita MI; Fujimoto T; Tanihara H Exp Eye Res; 2018 May; 170():160-168. PubMed ID: 29486164 [TBL] [Abstract][Full Text] [Related]
5. Cardioprotection induced by adenosine A1 receptor agonists in a cardiac cell ischemia model involves cooperative activation of adenosine A2A and A2B receptors by endogenous adenosine. Urmaliya VB; Church JE; Coupar IM; Rose'Meyer RB; Pouton CW; White PJ J Cardiovasc Pharmacol; 2009 May; 53(5):424-33. PubMed ID: 19333129 [TBL] [Abstract][Full Text] [Related]
6. A novel highly selective adenosine A1 receptor agonist VCP28 reduces ischemia injury in a cardiac cell line and ischemia-reperfusion injury in isolated rat hearts at concentrations that do not affect heart rate. Urmaliya VB; Pouton CW; Devine SM; Haynes JM; Warfe L; Scammells PJ; White PJ J Cardiovasc Pharmacol; 2010 Sep; 56(3):282-92. PubMed ID: 20571427 [TBL] [Abstract][Full Text] [Related]
7. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Abbracchio MP; Cattabeni F Ann N Y Acad Sci; 1999; 890():79-92. PubMed ID: 10668415 [TBL] [Abstract][Full Text] [Related]
8. Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives. Deb PK; Deka S; Borah P; Abed SN; Klotz KN Curr Pharm Des; 2019; 25(25):2697-2715. PubMed ID: 31333094 [TBL] [Abstract][Full Text] [Related]
9. Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Kristo G; Yoshimura Y; Keith BJ; Stevens RM; Jahania SA; Mentzer RM; Lasley RD Am J Physiol Heart Circ Physiol; 2004 Dec; 287(6):H2746-53. PubMed ID: 15271662 [TBL] [Abstract][Full Text] [Related]
10. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. Gao Z; Li Z; Baker SP; Lasley RD; Meyer S; Elzein E; Palle V; Zablocki JA; Blackburn B; Belardinelli L J Pharmacol Exp Ther; 2001 Jul; 298(1):209-18. PubMed ID: 11408544 [TBL] [Abstract][Full Text] [Related]
11. The effect of two selective A Cooper SL; March J; Sabbatini AR; Hill SJ; Jörg M; Scammells PJ; Woolard J Br J Pharmacol; 2020 Jan; 177(2):346-359. PubMed ID: 31596949 [TBL] [Abstract][Full Text] [Related]
12. Failure of CGS15943A to block the hypotensive action of agonists acting at the adenosine A3 receptor. Patel M; Sheehan MJ; Strong P Br J Pharmacol; 1994 Nov; 113(3):741-8. PubMed ID: 7858863 [TBL] [Abstract][Full Text] [Related]